Press release
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. & RESEARCH
About this update from United Therapeutics Corporation
Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis ( IPF ) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity ( FVC ) relative to placebo. Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p
View stock analysis, news, and events for United Therapeutics Corporation